RC
ABEO icon

Rangeley Capital’s Abeona Therapeutics ABEO Stock Holding History

Rangeley Capital’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$359K Sell
58,100
-1,900
-3% -$10.4K 0.33% 81
2026
Q1 		$269K Buy
60,000
+2,400
+4% +$12K 0.26% 81
2025
Q4 		$304K Buy
+57,600
New +$290K 0.25% 71

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rangeley Capital's ABEO Position: Q2 2026 in Review

Rangeley Capital reduced its Abeona Therapeutics (ABEO) stake by 3.2% in Q2 2026, selling an estimated $10.4K and leaving 58,100 shares worth $359K. The position accounts for 0.33% of the portfolio, ranked #81.

Rangeley Capital first reported a position in ABEO in Q4 2025 and has held it in 3 quarters since. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Rangeley Capital held 58,100 shares of Abeona Therapeutics worth $359K as of Q2 2026.
  • Rangeley Capital sold 1,900 Abeona Therapeutics shares in Q2 2026, an estimated $10.4K.
  • Abeona Therapeutics made up 0.33% of Rangeley Capital's portfolio in Q2 2026, its #81 holding.
  • Rangeley Capital first reported a position in Abeona Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.